Zynerba Pharma (ZYNE) Misses Q4 EPS by 33c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2015 Financial Results and Operational Highlights
March 14, 2016 7:00 AM EDTPositive Initial Phase 1 ZYN002 Single Rising Dose Results Reported; Phase 1 Multiple Rising Dose Trial Underway
FDA Grants ZYN002 Orphan-Drug Designation for Fragile X Syndrome
Three ZYN002 Phase 2a Trials Planned for Initiation in Second Half 2016
DEVON, Pa., March 14, 2016 (GLOBE NEWSWIRE) --... More



